GSK Unit Pushes Back On SEC In Stock Fraud Suit
By Carolina Bolado ( July 8, 2016, 9:39 PM EDT) -- Stiefel Laboratories Inc. pushed back Friday in Florida federal court against the U.S. Securities and Exchange Commission's bid for a win on claims that the pharmaceutical company and its ex-CEO defrauded investors and employees by rebuying undervalued stock before a $2.9 billion sale to GlaxoSmithKline PLC, arguing there are issues of fact a jury should hear....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.